Castle Biosciences (CSTL) Competitors $19.20 +0.04 (+0.18%) As of 10:40 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CSTL vs. PACS, CELC, LFST, NHC, ARDT, VRDN, TDOC, AHCO, GRAL, and PNTGShould you be buying Castle Biosciences stock or one of its competitors? The main competitors of Castle Biosciences include PACS Group (PACS), Celcuity (CELC), LifeStance Health Group (LFST), National HealthCare (NHC), Ardent Health (ARDT), Viridian Therapeutics (VRDN), Teladoc Health (TDOC), AdaptHealth (AHCO), GRAIL (GRAL), and The Pennant Group (PNTG). These companies are all part of the "healthcare" industry. Castle Biosciences vs. Its Competitors PACS Group Celcuity LifeStance Health Group National HealthCare Ardent Health Viridian Therapeutics Teladoc Health AdaptHealth GRAIL The Pennant Group PACS Group (NYSE:PACS) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends, media sentiment and profitability. Do insiders & institutionals hold more shares of PACS or CSTL? 92.6% of Castle Biosciences shares are held by institutional investors. 7.2% of Castle Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has better valuation and earnings, PACS or CSTL? PACS Group has higher revenue and earnings than Castle Biosciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPACS Group$3.11B0.56$112.87MN/AN/ACastle Biosciences$332.07M1.69$18.25M-$0.35-55.26 Is PACS or CSTL more profitable? PACS Group has a net margin of 0.00% compared to Castle Biosciences' net margin of -2.73%. Castle Biosciences' return on equity of 2.37% beat PACS Group's return on equity.Company Net Margins Return on Equity Return on Assets PACS GroupN/A N/A N/A Castle Biosciences -2.73%2.37%2.03% Which has more risk & volatility, PACS or CSTL? PACS Group has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Castle Biosciences has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Does the media favor PACS or CSTL? In the previous week, Castle Biosciences had 12 more articles in the media than PACS Group. MarketBeat recorded 16 mentions for Castle Biosciences and 4 mentions for PACS Group. Castle Biosciences' average media sentiment score of 0.86 beat PACS Group's score of 0.24 indicating that Castle Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PACS Group 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Castle Biosciences 5 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend PACS or CSTL? PACS Group presently has a consensus price target of $34.29, indicating a potential upside of 201.55%. Castle Biosciences has a consensus price target of $37.00, indicating a potential upside of 91.31%. Given PACS Group's higher possible upside, equities research analysts clearly believe PACS Group is more favorable than Castle Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score PACS Group 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Castle Biosciences 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCastle Biosciences beats PACS Group on 10 of the 14 factors compared between the two stocks. Get Castle Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for CSTL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CSTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CSTL vs. The Competition Export to ExcelMetricCastle BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$560.76M$3.00B$5.48B$9.72BDividend YieldN/A2.28%4.59%4.13%P/E Ratio-55.2317.0529.7624.63Price / Sales1.69347.15455.84102.60Price / Cash19.6840.7324.8127.99Price / Book1.198.898.595.76Net Income$18.25M-$54.75M$3.26B$264.95M7 Day Performance-4.96%-2.71%-0.35%-0.01%1 Month Performance-1.63%4.43%2.11%1.27%1 Year Performance-27.70%19.64%44.52%26.11% Castle Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CSTLCastle Biosciences3.2706 of 5 stars$19.20+0.2%$37.00+92.8%-28.6%$556.79M$332.07M-54.84540Analyst UpgradePACSPACS Group3.1283 of 5 stars$10.98+3.4%$34.29+212.3%-65.3%$1.62B$3.11B0.0032,433CELCCelcuity0.6285 of 5 stars$43.13+8.1%$39.20-9.1%+189.3%$1.55BN/A-14.2340Upcoming EarningsLFSTLifeStance Health Group3.2153 of 5 stars$3.90+2.9%$8.42+115.8%-18.4%$1.47B$1.28B-39.0010,218Earnings ReportAnalyst UpgradeNHCNational HealthCareN/A$94.77+0.2%N/A-15.8%$1.47B$1.37B11.8812,400Dividend AnnouncementARDTArdent Health3.9387 of 5 stars$10.32+1.0%$20.30+96.7%-23.0%$1.46B$5.97B6.3324,900Earnings ReportAnalyst UpgradeAnalyst RevisionVRDNViridian Therapeutics1.8252 of 5 stars$16.86-3.2%$37.00+119.5%+12.5%$1.42B$300K-4.3850Trending NewsEarnings ReportAnalyst RevisionTDOCTeladoc Health2.9681 of 5 stars$6.98+0.6%$9.76+39.9%-5.1%$1.23B$2.57B-5.875,500Positive NewsAHCOAdaptHealth3.9353 of 5 stars$9.11+4.1%$13.40+47.1%-1.0%$1.18B$3.26B15.9810,500Analyst UpgradeGRALGRAIL1.2675 of 5 stars$33.23+1.3%$31.50-5.2%+102.3%$1.18B$125.60M-0.541,360PNTGThe Pennant Group3.424 of 5 stars$22.16+0.4%$33.80+52.5%-13.7%$760.73M$695.24M29.167,000Analyst Upgrade Related Companies and Tools Related Companies PACS Group Alternatives Celcuity Alternatives LifeStance Health Group Alternatives National HealthCare Alternatives Ardent Health Alternatives Viridian Therapeutics Alternatives Teladoc Health Alternatives AdaptHealth Alternatives GRAIL Alternatives The Pennant Group Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CSTL) was last updated on 8/12/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredWhy Elon put $51 million into thisChris Rowe has made legendary calls—Tesla at $13, Nvidia at $40, Bitcoin under $1,000, Amazon at 12 cents. Now...True Market Insiders | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredSell these stocks now—what to buy insteadWall Street veteran Marc Chaikin—creator of the Power Gauge system—is warning that “smart money” is rapidly pu...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Castle Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Castle Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access